cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients
Services
Services
Date issued
2013Journal title
Hepatology
Type of content
Publicación de congreso
